DexCom Valuation Multiples

Discover DexCom's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Philips, Mettler Toledo, Illumina, GE HealthCare and more.

DexCom Overview

About DexCom

DexCom designs and commercializes continuous glucose monitoring systems for diabetic patients. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to provide integration with insulin pumps from Insulet and Tandem for automatic insulin delivery. DexCom's CGMs are available through medical equipment distributors as well as retail pharmacies.


Founded

1999

HQ

United States

Employees

11.1K

Website

dexcom.com

Financials (LTM)

Revenue: $5B
EBITDA: $1B

EV

$26B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DexCom Financials

DexCom reported last 12-month revenue of $5B and EBITDA of $1B.

In the same LTM period, DexCom generated $3B in gross profit, $1B in EBITDA, and $915M in net income.

Revenue (LTM)


DexCom P&L

In the most recent fiscal year, DexCom reported revenue of $5B and EBITDA of $1B.

DexCom is profitable as of last fiscal year, with gross margin of 60%, EBITDA margin of 29%, and net margin of 18%.

See analyst estimates for DexCom
LTMLast FY202320242025202620272028
Revenue$5B$5B$4B$4B$5B
Gross Profit$3B$3B$2B$2B$3B
Gross Margin62%60%63%60%60%
EBITDA$1B$1B$917M$946M$1B
EBITDA Margin30%29%25%23%29%
EBIT Margin22%21%17%15%20%
Net Profit$915M$836M$542M$576M$836M
Net Margin18%18%15%14%18%
Net Debt-$323M---

Financial data powered by Morningstar, Inc.

DexCom Stock Performance

DexCom has current market cap of $27B, and enterprise value of $26B.

Market Cap Evolution


DexCom's stock price is $71.25.

DexCom share price increased by 5.8% in the last 30 days, and decreased by 11.8% in the last year.

DexCom has an EPS (earnings per share) of $2.17.

See more trading valuation data for DexCom
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$26B$27B0.0%5.8%19.6%-11.8%$2.17

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DexCom Valuation Multiples

DexCom trades at 5.3x EV/Revenue multiple, and 17.7x EV/EBITDA.

See NTM and 2027E valuation multiples for DexCom

EV / Revenue (LTM)


DexCom Financial Valuation Multiples

As of July 4, 2026, DexCom has market cap of $27B and EV of $26B.

DexCom has a P/E ratio of 30.1x.

LTMLast FY202320242025202620272028
EV/Revenue5.3x5.7x7.3x6.6x5.7x
EV/EBITDA17.7x19.5x28.9x28.0x19.5x
EV/EBIT24.2x27.3x44.3x44.1x29.0x
EV/Gross Profit8.6x9.4x11.6x10.9x9.4x
P/E30.1x32.9x50.8x47.7x32.9x
EV/FCF21.2x18.6x51.7x42.0x24.6x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DexCom Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DexCom Margins & Growth Rates

DexCom grew revenue by 12% and EBITDA by 21% in the last fiscal year.

In the most recent fiscal year, DexCom reported gross margin of 60%, EBITDA margin of 29%, and net margin of 18%.

See estimated margins and future growth rates for DexCom

DexCom Margins

Last FY202420252026202720282029
Gross Margin60%60%60%63%
EBITDA Margin29%23%29%31%
EBIT Margin21%15%20%23%
Net Margin18%14%18%19%
FCF Margin31%16%23%21%

DexCom Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth12%11%16%12%
Gross Profit Growth18%7%15%18%
EBITDA Growth21%3%44%21%
EBIT Growth25%0%52%33%
Net Profit Growth19%6%45%19%
FCF Growth(25%)23%71%(0%)

Data powered by FactSet, Inc. and Morningstar, Inc.

DexCom Operational KPIs

DexCom's revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.2M for the same period.

DexCom's Rule of 40 is 43% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DexCom's Rule of X is 62% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DexCom
LTMLast FY202320242025202620272028
Rule of 4042%43%---
Bessemer Rule of X60%62%---
Revenue per Employee-$0.4M---
Opex per Employee-$0.2M---
R&D Expenses to Revenue13%13%14%14%13%
Opex to Revenue-41%47%46%41%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

DexCom Competitors

DexCom competitors include Philips, Mettler Toledo, Illumina, GE HealthCare, Mindray, ResMed, Alcon, Steris, Sartorius and Halma.

Most DexCom public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Philips1.6x1.6x9.7x9.6x
Mettler Toledo7.1x6.9x22.8x22.1x
Illumina6.9x6.7x20.5x23.9x
GE HealthCare1.8x1.8x10.1x10.2x
Mindray4.6x4.4x13.3x13.6x
ResMed5.8x5.3x15.4x13.5x
Alcon3.5x3.5x13.6x13.4x
Steris3.9x3.8x13.6x13.3x

This data is available for Pro users. Sign up to see all DexCom competitors and their valuation data.

Start Free Trial

Acquisitions by DexCom

DexCom has acquired 3 companies to date.

Last acquisition by DexCom was on June 3rd 2026. DexCom acquired Nutrisense for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by DexCom

Nutrisense
TypeZero Technologies
Nintamed
Description
Nutrisense is a Chicago-headquartered health platform offering continuous glucose monitoring via partnerships with Dexcom and Abbott Freestyle Libre, paired with an app for real-time insights and personalized coaching. Users track meals, exercise, and sleep to optimize metabolic health. Founded in 2019, the company serves 50,000 members with machine learning algorithms validated in studies published in journals like Nutrients.
TypeZero Technologies is a Charlottesville, Virginia-based medical device company offering the inControl automated insulin delivery system for type 1 diabetes management. Acquired by United Therapeutics in 2018 after pivotal trials demonstrating improved time-in-range metrics, its FDA-cleared platform integrates continuous glucose monitors with insulin pumps for closed-loop control. TypeZero collaborates with Dexcom and Tandem Diabetes Care to simplify therapy for over 1.25 million U.S. patients.
Nintamed is a medical device distributor operating in Germany, Switzerland, and Austria. Munich-headquartered, it supplies endoscopy equipment, surgical robots, and diagnostic imaging systems from brands like Karl Storz and Olympus. The company maintains certified warehouses in Zurich and Vienna, offering training academies and maintenance contracts. Nintamed serves hospitals and clinics with just-in-time delivery and CE-marked inventory.
HQ CountryUnited StatesUnited StatesGermany
HQ City
Chicago, IL
Charlottesville, VA
Mainz
Deal Date3 Jun 202622 Aug 20182 May 2016
Valuationundisclosed$11M$7M
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DexCom acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by DexCom

DexCom has invested in 5 companies to date.

Latest investment by DexCom was on May 26th 2026. DexCom invested in Signos in their $20M Undisclosed stage round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by DexCom

Signos
Oura
Phenomix Sciences
Current Health
Description
Signos is a health technology company combining continuous glucose monitoring with AI-driven coaching for weight management. The app delivers personalized dietary recommendations based on real-time metabolic data to stabilize glucose and promote fat loss. Launched in the United States, Signos targets obesity through wearable sensors and habit optimization.
Oura is a Helsinki-headquartered company founded in 2013 that manufactures the Oura Ring Gen3, a finger-worn sensor tracking heart rate, blood oxygen, temperature, and sleep stages. The companion app delivers readiness, activity, and recovery scores used by professional athletes and over 10 million app downloads worldwide. Available in the US, Europe, and Asia through direct sales and retailers like Best Buy.
Phenomix Sciences is a New York-headquartered biotechnology firm specializing in pharmacogenomics for chronic disease management including diabetes and cardiovascular conditions. Its testing panels analyze metabolomics and genetic markers to tailor medications reducing adverse effects. Founded in 2017, the company partners with clinics nationwide offering CLIA-certified lab services processed in under 48 hours.
Current Health is a London-headquartered remote patient monitoring platform enabling virtual care delivery for hospitals and health systems. The company provides wearable devices, AI analytics, and clinician dashboards to track vital signs like heart rate, oxygen levels, and activity in chronic disease patients. Acquired by Best Buy Health in 2021, it serves providers across the United States and United Kingdom, including partnerships with the National Health Service and major insurers. Deployed in over 100 hospitals, the platform supports post-discharge management and telehealth integrations.
HQ CountryUnited StatesFinlandUnited StatesUnited States
HQ City
San Francisco, CA
Oulu
Rochester, MN
Boston, MA
Deal Date26 May 202619 Nov 20246 May 202417 Jun 2020
RoundUndisclosed stageSeries DSeries ASeries A
Raised$20M$200M$6M$4M
InvestorsGV; Blue Cross and Blue Shield of Alabama; DexComTemasek; Fidelity; Andreessen Horowitz; DexComHealth2047; Labcorp; DexComPar Equity; Legal & General; DexCom; MMC Ventures
Valuationundisclosed$5Bundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DexCom investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DexCom

When was DexCom founded?DexCom was founded in 1999.
Where is DexCom headquartered?DexCom is headquartered in United States.
How many employees does DexCom have?As of today, DexCom has over 11K employees.
Who is the CEO of DexCom?DexCom's CEO is Jacob S. Leach.
Is DexCom publicly listed?Yes, DexCom is a public company listed on Nasdaq.
What is the stock symbol of DexCom?DexCom trades under DXCM ticker.
When did DexCom go public?DexCom went public in 2005.
Who are competitors of DexCom?DexCom main competitors include Philips, Mettler Toledo, Illumina, GE HealthCare, Mindray, ResMed, Alcon, Steris, Sartorius, Halma.
What is the current market cap of DexCom?DexCom's current market cap is $27B.
What is the current revenue of DexCom?DexCom's last 12 months revenue is $5B.
What is the current revenue growth of DexCom?DexCom revenue growth (NTM/LTM) is 12%.
What is the current EV/Revenue multiple of DexCom?Current revenue multiple of DexCom is 5.3x.
What is the current EBITDA of DexCom?DexCom's last 12 months EBITDA is $1B.
What is DexCom's EBITDA margin?DexCom's last 12 months EBITDA margin is 30%.
What is the current EV/EBITDA multiple of DexCom?Current EBITDA multiple of DexCom is 17.7x.
What is the current FCF of DexCom?DexCom's last 12 months FCF is $1B.
What is DexCom's FCF margin?DexCom's last 12 months FCF margin is 25%.
What is the current EV/FCF multiple of DexCom?Current FCF multiple of DexCom is 21.2x.
How many companies DexCom has acquired to date?As of July 2026, DexCom has acquired 3 companies.
What was the largest acquisition by DexCom?$11M acquisition of TypeZero Technologies on 22nd August 2018 was the largest M&A DexCom has done to date.
What companies DexCom acquired?DexCom acquired TypeZero Technologies, Nintamed, and Nutrisense.
In how many companies DexCom has invested to date?As of July 2026, DexCom has invested in 5 companies.
What was the last DexCom investment?On 26th May 2026 DexCom invested in Signos, participating in a $20M Undisclosed stage round, alongside GV and Blue Cross and Blue Shield of Alabama.
In what companies DexCom invested in?DexCom invested in Oura, Beta Bionics, Signos, Phenomix Sciences, and Current Health.

See public comps similar to DexCom

Lists including DexCom

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial